Jefferies Assumes Aclaris Therapeutis (ACRS) at Buy

July 23, 2021 7:49 AM EDT
Get Alerts ACRS Hot Sheet
Price: $18.07 +0.33%

Rating Summary:
    7 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 5 | New: 36
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Jefferies analyst Roger Song assumes coverage on Aclaris Therapeutis (NASDAQ: ACRS) with a Buy rating and a price target of $32.00 (from $27.00).

The analyst commented, "Aclaris has transformed into precision immunology biotech w/ two lead programs in Ph2 and each w/ blockbuster potential. Lead ATI-450, first-in-class MK2 inhibitor, showed impressive efficacy/safety in Ph2a rheumatoid arthritis, and will have Ph2b data in 1H23. ATI-1777, topical JAK1/3 inhibitor, showed encouraging profile in Ph2a atopic dermatitis and will have Ph2b data in 2H23. We assume coverage at Buy, w/ PT of $32 (vs. prev. 27), driven by '450/'1777."

For an analyst ratings summary and ratings history on Aclaris Therapeutis click here. For more ratings news on Aclaris Therapeutis click here.

Shares of Aclaris Therapeutis closed at $15.61 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change, New Coverage

Related Entities

Jefferies & Co